Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib versus best supportive care in newly diagnosed acute myeloid leukemia in patients aged 70 years or older
2004-001719-77Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Tipifarnib with Best supportive care including hydroxyurea (2 arms). Primary endpoint: Overall survival. Started Sep 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2004-001719-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001719-77.